Impact of angiotensin-converting enzyme inhibition on renal cortical nitrotyrosine content during increased extracellular glucose concentration.

Clinical Biochemistry
Naohito IshiiMasato Katagiri

Abstract

Experiments evaluated the hypothesis that angiotensin-converting enzyme (ACE) inhibition suppresses hyperglycemia-induced nitrotyrosine (NT) production in the renal cortex. Rats were untreated (UNTR, n = 6) or received the ACE inhibitor enalapril (20 mg/kg/day; ENAL, n = 6) for 2 weeks. Renal cortical slices were incubated for 90 min in media containing 5 (normal) or 20 mmol/L (high) glucose. Superoxide anion (O2*-) and nitrate + nitrite (NO(X)) levels were measured in the media. Superoxide dismutase (SOD) activity and NT content were measured in the tissue homogenate. In the UNTR group, high glucose increased O2*- and NO(X) production by the renal cortex (P < 0.05 vs. normal glucose). Likewise, NT content and SOD activity of the renal cortex augmented (P < 0.05 vs. normal glucose). In the ENAL group, O2*- production and NT content were glucose-insensitive, but high glucose exerted an exaggerated impact on NO(X) production and SOD activity (P < 0.01 vs. UNTR in high glucose). Accelerated NT content in the renal cortex during high-glucose conditions was prevented by ACE inhibitor treatment. It was suggested that, apart from its anti-hypertensive effect, the mechanism of suppressed NT degradation in the renal cortex by the ACE in...Continue Reading

References

Nov 1, 1992·The Journal of Clinical Investigation·P J Shultz, L Raij
Feb 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·J S BeckmanB A Freeman
Jun 1, 1990·Kidney International·B H RovinD E Kohan
Sep 23, 1994·Cell·C Nathan, Q W Xie
Feb 1, 1995·Journal of the American Society of Nephrology : JASN·K Ohishi, P K Carmines
Jul 1, 1996·Chemical Research in Toxicology·J S Beckman
Nov 1, 1996·The American Journal of Physiology·J S Beckman, W H Koppenol
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·Y KamisakiF Murad
Mar 17, 2000·Circulation Research·K K GriendlingM Ushio-Fukai
Nov 23, 2000·Nature·T Finkel, N J Holbrook
Mar 27, 2001·Annual Review of Pharmacology and Toxicology·K L DavisF Murad
Jul 20, 2001·Journal of the American Society of Nephrology : JASN·Naohito IshiiPamela K Carmines
Sep 13, 2001·Clinical and Experimental Pharmacology & Physiology·K SugimotoA Fujimura
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Nov 17, 2001·Hypertension·E M de CavanaghL Ferder
Jan 12, 2002·Kidney International·Maristela Lika OnozatoChristopher S Wilcox
May 7, 2002·International Journal of Experimental Diabetes Research·Lisa M Harrison-BernardPamela K Carmines
Nov 14, 2002·Pharmacological Reviews·Illarion V Turko, Ferid Murad
Mar 20, 2003·Comparative Biochemistry and Physiology. Toxicology & Pharmacology : CBP·Supatra PorasuphatanaGerald M Rosen
May 29, 2004·Arteriosclerosis, Thrombosis, and Vascular Biology·Frank M Faraci, Sean P Didion
Jul 16, 2004·Metabolism: Clinical and Experimental·Naohito IshiiTetsuya Suga
Jul 17, 2004·Clinica Chimica Acta; International Journal of Clinical Chemistry·Mosaad A Abou-Seif, Abd-Allah Youssef

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.